Hold On TG’s Program Stems From Existing – Not New – Concerns
‘Sub-par’ Disclosure Draws Analyst Finger Wagging
Executive Summary
TG expects overall survival hazard ratios to move closer to those of existing CLL drugs. Some analysts called a drop in the company’s shares overblown.
You may also be interested in...
Bayer Pulls Aliqopa Combo Filings In EU, US & Other Markets – But May Resubmit
The company plans to conduct additional analyses of data from ongoing trials that are testing its PI3K inhibitor in combination with rituximab for treating types of indolent B-cell non-Hodgkin’s lymphoma.
‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals
Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due to confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.
Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck
The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker